BIOMARK’S COLLABORATOR RECEIVES FUNDING TO VALIDATE ITS BIOMARKER PANEL FOR THE EARLY DETECTION OF LUNG CANCER

biomarks collaborator receives funding to validate its biomarker panel

Vancouver, British Columbia – (March 16, 2021) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce today that its sponsored research collaboration with The Metabolomics Innovation Centre (TMIC) was successful in receiving funding from the Novel Technology Application in Cancer Prevention and Early Detection Spark Grants competition. This comes […]

BIOMARK TEAM INVITED FOR FULL APPLICATION FOR SPARKS GRANT COMPETITION

biomark team invited for full application for sparks grant competition

Vancouver, British Columbia – (September 14th, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that 2 of its most recent abstract submissions for the Novel Technology Application in Cancer Prevention and Early Detection Spark Grants competition have resulted in invitations to submit full applications for funding. This […]

BIOMARK TEAM SECURES HEALTH CANADA LETTER OF NO OBJECTION FOR ITS GLIOBLASTOMA CLINICAL TRIAL

biomark team secures health canada letter of no objection for its blioblastoma clinical trial

Vancouver, British Columbia – (August 27th, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that Health Canada has approved its clinical trial application (CTA) and has granted a Letter of No Objection (NOL) for its application entitled ACETYL-AMANTADINE AS A BIOMARKER IN PATIENTS WITH GLIOBLASTOMA. The company […]

BIOMARK’S LIQUID BIOPSY ASSAY LEVERING METABOLOMICS DEMONSTRATES STRONG PERFORMANCE FOR EARLY LUNG CANCER DETECTION

Vancouver, British Columbia – ( March 24th, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that the article “A High-Performing Plasma Metabolite Panel for Early-Stage Lung Cancer Detection” has been published in the peer-reviewed journal Cancers, validating BioMark’s technology to detect early-stage (I/II) non-small cell lung cancer […]